Our specialized units cover diverse therapeutic areas such as endocrinology, metabolic disorders, cardiology, gastroenterology, women’s health, dermatology, hematology, and nephrology.
June 11-12, Leipzig, Germany
Head of Business Development
christian.bozler@crs-group.de
We’re excited to attend the 1st Annual European Biopharma Obesity Innovation Forum on 11–12 June 2025 in Leipzig, Germany. This landmark conference will spotlight the future of GLP-1 development, innovative combination therapies, and advancements in precision medicine. It will also explore manufacturing challenges and provide insights into the evolving European market and its global impact.
Our Chief Medical Officer, Dr. Thomas Forst, will present “Accelerating Early Drug Development in Obesity and Metabolic Syndromes: Strategies for Success” on Wednesday, June 11th, at 1:50 PM in Ballroom Track B.
We invite you to attend the session and connect with the CRS team on-site to learn how our early-phase expertise can support your obesity and metabolic drug development programs.
With over 45 years of experience in running Phase I-II trials across multiple therapeutic areas, CRS offers comprehensive clinical research services that support the rapid development of new medicines. Our expertise includes managing early-phase clinical trials from First-in-Human to Proof-of-Concept, ensuring high-quality results that adhere to the highest standards of safety and regulatory compliance.
A key highlight of our work includes our collaboration with leading pharmaceutical companies, providing seamless services from study design through to data analysis. Our ability to conduct complex studies in challenging therapeutic areas has been instrumental in the successful development of novel treatments.
CRS operates world-class clinical trial facilities and maintains a network of specialized labs and hospitals to support a wide range of clinical research needs. Our integrated approach, which includes Pre-/Non-Clinical consultancy services at Venn Life Sciences, ensures that studies are executed with the highest level of scientific rigor, regulatory compliance, and operational efficiency.
CRS Clinical Research Services is one of Europe’s leading Early Phase Clinical Research Organizations (CROs), specializing in Phase I and II trials. With over 45 years of experience, CRS delivers high-quality, patient-centered clinical research across a broad spectrum of therapeutic areas.
Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.
hVIVO is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services for their broad and longstanding global client base of biopharma companies.
Connect with us on Linkedin!